NCT07705568 EYS-611 Age Related Macular Degeneration Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07705568—An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07705568 is a hot trial to watch

Age Related Macular Degeneration is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. NCT07705568 is notable because it tests EYS-611 in a Phase 2 design while Frequency and severity of ocular and non-ocular adverse events (Safety and Tolerability) serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Enrollment of 24 participants across France shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

• Primary: Frequency and severity of ocular and non-ocular adverse events (Safety and Tolerability) — Screening to week 52
• Secondary: Intraocular pressure — Screening to week 52
• Secondary: Best corrected visual acuity — Screening to week 52
• Secondary: Slit lamp biomicroscopy examination — Screening to week 52
• Secondary: Dilated ophthalmoscopy examination — Screening to week 52

Benchmark readouts in the surrounding field

• Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy (Phase 2): Percent of Subjects With ≥ 2-step Improvement in Diabetic Retinopathy Severity Score (DRSS) = 41 Participants ; Percent of Subjects With ≥ 2-step Improvement in Diabetic Retinopathy Severity Score (DRSS) = 39 Participants
• COMPARE COMBINED USE OF ANTI-VEGF DRUGS DURING OR AFTER PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA GUIDED BY MICROSCOPE-INTEGRATED OPTICAL COHERENCE TOMOGRAPHY (Phase 3): BCVA(1 month) = 10.0 letters ; BCVA(1 month) = 8.0 letters
• A Study in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration to Evaluate a High Dose Aflibercept (8 mg) Prefilled Syringe (Phase 3): Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS = 35 injections

These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: EYS-611 (Phase 2; target not reported)

Company & Deal Intelligence context: Eyevensys SAS — http://www.eyevensys.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07705568 is a focused lens on Age Related Macular Degeneration development. Its value will be determined by whether EYS-611 can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.